Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343876 · ClinicalTrials.gov registry record · Phase 4
Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial
A Phase 4 study, sponsored by Intermountain Health Care.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00343876 is a Phase 4 study that has completed, run by Intermountain Health Care. The registered enrollment target is 100 participants.
The verdict
NCT00343876, a Phase 4 study, has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Inflammation is associated with worsening outcomes among individuals with CAD; C-reactive protein is a well-known marker of inflammation. Both healthy patients and those with a history of CAD who exhibit elevated CRP are at greater risk for cardiovascular events. Despite CRP's well- documented association with increased risk in the development and progression of CAD, the specific mechanism of elevated CRP in CAD is not known. One possible etiology includes a continuous prothrombotic process associated with CAD. Several studies demonstrate a link between platelet activation and inflammation. If thrombotic processes are involved in the mechanism of elevated CRP, antiplatelet therapy, including clopidogrel, could effectively reduce CRP. Preliminary studies have demonstrated a reduction of CRP with aspirin and a clear association between clopidogrel therapy and reduced CRP, however no randomized trials have been performed. We hypothesize that the proinflammatory effects of platelet activation may be inhibited with combined clopidogrel and aspirin therapy.
Interventions
- DRUG aspirin
- DRUG clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00343876
The ClinicalTrials.gov registry entry for NCT00343876 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intermountain Health Care, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aspirin is the first listed.
NCT00343876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00343876 about?
NCT00343876 is a clinical study titled "Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial". Inflammation is associated with worsening outcomes among individuals with CAD; C-reactive protein is a well-known marker of inflammation. Both healthy patients and those with a history of CAD who exhibit elevated CRP are at greater risk for cardiovascular events. Despite CRP's well- documented assoc...
What is the current status of trial NCT00343876?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2005-07. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00343876?
The interventions under investigation include: aspirin (DRUG), clopidogrel (DRUG).
Who is sponsoring clinical trial NCT00343876?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.